Stay updated on Nivolumab in Resectable NSCLC Clinical Trial

Sign up to get notified when there's something new on the Nivolumab in Resectable NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab in Resectable NSCLC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value 7 on the webpage has recently changed to 8. This change likely represents an update or amendment to a study involving the evaluation of preoperative administration of nivolumab +/- ipilimumab in patients with high-risk resectable NSCLC, aiming to explore the safety, feasibility, and efficacy of immunotherapies in this patient population.
    Difference
    0.0%
    Check dated 2024-06-06T14:24:46.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The webpage section 'Participation Criteria Study Record Updates' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change includes detailed inclusion and exclusion criteria for participants with non-small-cell lung cancer.
    Difference
    16%
    Check dated 2024-05-22T21:01:27.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.3%
    Check dated 2024-04-30T22:48:58.000Z thumbnail image

Stay in the know with updates to Nivolumab in Resectable NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab in Resectable NSCLC Clinical Trial page.